Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 5, August, p. 835–842

doi: 10.17219/acem/61434

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Serum ICAM-1, VCAM-1 and E-selectin levels in patients with primary and secondary Sjögren’s syndrome

Katarzyna J. Błochowiak1,A,B,C,D,F, Anna Olewicz-Gawlik2,A,B,E,F, Dorota Trzybulska2,C,D,E,F, Michalina Nowak-Gabryel3,B,E,F, Jarosław Kocięcki3,E,F, Henryk Witmanowski4,E,F, Jerzy Sokalski1,A,E,F

1 Department of Oral Surgery, Poznan University of Medical Sciences, Poland

2 Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poland

3 Department of Ophthalmology, Poznan University of Medical Sciences, Poland

4 Department of Plastic, Reconstructive and Aesthetic Surgery, Nicolaus Copernicus University Torun, Collegium Medicum, Bydgoszcz, Poland


Background. Typical features of Sjögren’s syndrome (SS) are severe xerostomia and xerophthalmia which are basic diagnostic criteria.
Objectives. The aim of this study was to compare the serum levels of soluble (s) intercellular adhesion molecule 1 (sICAM-1), vascular cell adhesion molecule 1 (sVCAM-1) and sE-selectin between primary (pSS), secondary (sSS) and healthy subjects (HS). We correlated these results with selected clinical parameters of disease activity and parameters of the severity of xerostomia and xerophthalmia.
Material and Methods. The serum levels of sICAM-1, sVCAM-1 and sE-selectin were determined by enzyme-linked immunosorbent assay (ELISA) in 16 patients with pSS, 18 with sSS and 15 HS. Eye dryness and xerostomia were assessed by the Schirmer’s test, the Fox test and the visual analogue scale (VAS).
Results. The levels of sICAM-1 in pSS and sVCAM-1 in sSS patients were significantly higher when compared to HS (p = 0.02 and p = 0.048, respectively). There were no differences between pSS and sSS. In pSS, sVCAM-1 correlated positively with VAS (rS = 0.52, p = 0.04) and the Fox test (rS = 0.66, p=0.01). In sSS, sE-selectin correlated positively with sICAM-1 (rS = 0.54, p = 0.01), the duration of the disease (rS = 0.51, p = 0.03) and negatively with the Schirmer’s test (rS = 0.59, p = 0.04). sICAM-1 correlated positively with the erythrocyte sedimentation rate (ESR) value (rS = 0.59, p = 0.01).
Conclusion. sVCAM-1 reflects xerostomia in pSS. sICAM-1 and sE-selectin may be additional parameters of sSS activity.

Key words

Sjögren’s syndrome, xerostomia, sICAM-1, sE-selectin, sVCAM-1

References (28)

  1. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med. 2002;6:357–376.
  2. Lisi S, Sisto M, D’Amore M, Lofrumento DD. Emerging avenues linking inflammation, angiogenesis and Sjögren syndrome. Cytokine. 2013;61:693–703.
  3. Kapsogeorgou EK, Dimitriou R, Abu-Helu F, Moutsopoulos M, Manonssakis MN. Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sjögren’s syndrome: High expression of intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells. Clin Exp Immunol. 2001;124:126–133.
  4. Turkcapar N, Sak SD, Saatci M, Duman M, Olmez U. Vasculitis and expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and e-selectin in salivary glands of patients with Sjögren’s syndrome. J Rheumatol. 2005;32:1063–1070.
  5. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjögren’s syndrome: Why autoimmune epithelitis? Oral Diseases. 2006;12:523–532.
  6. Vitali C, Bombardieri S, Jonsson R. Classification criteria for Sjögren syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–558.
  7. Fox RI, Liu AY. Sjögren’s syndrome in dermatology. Clinics in Dermatology. 2006;24:393–413.
  8. Fox RI. Sjögren’s syndrome. Lancet. 2005;366:321–331.
  9. Carr AJ, Ng WF, Figueiredo F, Macleod RI, Greenwood M, Stainers K. Sjögren’s syndrome-an update for dental practitioners. Br Dental J. 2012;213:353–357.
  10. Malicka B, Kaczmarek U, Skośkiewicz-Malicka K. Prevalance of xerostomia and salivary flow rate in diabetic patients. Adv Clin Exp Med. 2014;23:225–233.
  11. Wörnberg Gerdin E, Einarson S, Jonsson M, Aronsson K, Johansson I. Impact of dry mouth conditions on oral health-related quality of life in older people. Gerodontology. 2005;22:219–226.
  12. Jamison RN, Gracely RH, Raymond SA, et al. Comparative study of electronic vs paper VAS ratings: A randomized, crossover trial using healthy volunteers. Pain. 2002;99:341–347.
  13. Bolognese JA, Schnitzer TJ, Ehrich EW. Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. Osteoarthritis Cartilage. 2003;11:499–507.
  14. Moriyama M, Hayashida JN, Toyoshima T, et al. Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjögren’s syndrome. Clin Exp Immunol. 2012;169:17–26.
  15. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren’s syndrome. Oral Diseases. 2009;15:519–526.
  16. Steinfeld S, Simonart T. New approaches to the treatment of Sjögren’s syndrome: Soon beyond symptomatic relief? Dermatology. 2003;207:6–9.
  17. Voulgarelis M, Tzioufaz AG. Pathogenetic mechanisms in the initianion and perpetuation of Sjögren’s syndrome. Nat Rev Rheumatol. 2010;9:529–537.
  18. Gerli R, Vaudo G, Bocci EB, et al. Functional impairment of the arterial wall in primary Sjögren’s syndrome: combined action of immunologic and inflammatory factors. Arthritis Care Res (Hoboken). 2010;62:712–718.
  19. Sisto M, Lisi S, Ingravallo G, Lofrumento DD, D’Amore M, Ribatti D. Neovascularization is prominent in the chronic inflammatory lesions of Sjögren’s syndrome. Int J Exp Path. 2014;95:131–137.
  20. Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol. 2007;27:246–256.
  21. Sisto M, Lisi S, Lofrumento DD, D’Amore M, Frassanito MA, Ribatti D. Sjögren’s syndrome pathological neovascularization is regulated by VEGF-A stimulated TACE-dependent crosstalk between VEGFR2 and NF-κB. Genes Immun. 2012;13:411–420.
  22. Salliot C, Mouthon L, Ardizzone M, et al. Sjögren’s syndrome is associated with and not secondary to systemic sclerosis. Rheumatology. 2007;46:321–326.
  23. Hernández-Molina G, Ávilo-Casado C, Cárdenas-Veiázquez F, et al. Similarities and differences between primary and secondary Sjögren’s syndrome. J Reumathol. 2010;37:800–808.
  24. Gao J, Morgan G, Tieu D, et al. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Exp Eye Res. 2004;78:823–835.
  25. Egerer K, Feiste E, Rohr U, Pruss A, Burmester GR, Dörner T. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus. 2000;9:614–621.
  26. Bertorello R, Codone MP, Contini P, et al. Increased levels of interleukin-10 in saliva of Sjögren’s syndrome patients: Correlation with disease activity. Clin Exp Med. 2004;4:148–151.
  27. Seror R, Vitali C, Ravaud P, et al. EULAR Sjögren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis. 2010;69:1103–1109.
  28. Seror R, Theander E, Bootsma H, et al. Outcome measures for primary Sjögren’s syndrome: A comprehensive review. J Autoimmun. 2014;51:51–56.